R Squared Ltd Buys New Stake in Lexicon Pharmaceuticals, Inc. $LXRX

R Squared Ltd bought a new stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the second quarter, Holdings Channel reports. The firm bought 29,559 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Straight Path Wealth Management acquired a new position in Lexicon Pharmaceuticals in the 1st quarter valued at $29,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Lexicon Pharmaceuticals in the 1st quarter worth $32,000. CWM LLC grew its position in Lexicon Pharmaceuticals by 9,228.4% in the 1st quarter. CWM LLC now owns 105,504 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 104,373 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in Lexicon Pharmaceuticals by 77.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 28,594 shares during the last quarter. Finally, Cerity Partners LLC grew its position in Lexicon Pharmaceuticals by 76.5% in the 1st quarter. Cerity Partners LLC now owns 170,387 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 73,875 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX opened at $1.42 on Monday. The firm has a market cap of $516.03 million, a PE ratio of -4.30 and a beta of 1.23. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $2.08. The company has a quick ratio of 4.16, a current ratio of 4.16 and a debt-to-equity ratio of 0.43. The company’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $0.98.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. Lexicon Pharmaceuticals had a negative net margin of 206.43% and a negative return on equity of 83.63%. The company had revenue of $28.87 million for the quarter, compared to analyst estimates of $4.87 million. On average, equities analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Citigroup raised their price target on shares of Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Saturday. Wall Street Zen upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, October 4th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research report on Tuesday, September 2nd. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.23.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.